Mr. Joshua A. Kazam is an Independent Director at Soaring Eagle Acquisition Corp., an Independent Director at Tishman Speyer Innovation Corp. II, an Independent Director at TS Innovation Acquisitions Corp., a Director & Partner at Vida Ventures LLC, a Partner at Two River Consulting LLC, a Director & Co-Owner at Riverbank Capital Securities, Inc., a Co-Founder & Partner at Two River Group Holdings LLC, a Co-Founder at VV Manager LLC, a Director & Vice President at Two River Group Management LLC, a Member-Executive Board at The Wharton School of the University of Pennsylvania and a Principal at BCIF Pty Ltd. He is on the Board of Directors at Soaring Eagle Acquisition Corp., Tishman Speyer Innovation Corp. II, TS Innovation Acquisitions Corp., Breakthrough Properties LLC, Breakthrough Services LLC, Allogene Therapeutics, Inc., Vida Ventures LLC, Kronos Bio, Inc., ByHeart, Inc., Desert Flower Foundation GmbH, Vision Path, Inc., MedPod, Inc., Veterinary Prime, Inc., Riverbank Capital Securities, Inc., 105 W First Street LLC, Cortiva Therapy, Danube Pharmaceuticals, Inc., Kirax Corp., Tranzutary Holdings LLC, Vetprime, Inc. and Two River Group Management LLC. Mr. Kazam was previously employed as an Independent Director by Flying Eagle Acquisition Corp., an Independent Director by Diamond Eagle Acquisition Corp., an Independent Director by Platinum Eagle Acquisition Corp., an Independent Director by Capricor Therapeutics, Inc., a Director-Investment Management by Orion Biomedical Fund LP, a Managing Director by Paramount BioCapital, Inc., and a Chief Executive Officer & Director by IconOVir Bio, Inc. He also served on the board at Kite Pharma, Inc., Velcera, Inc., Arno Therapeutics, Inc., Nile Therapeutics, Inc. /Old/, Arno Therapeutics, Inc. /Old/, Manhattan Pharmaceuticals, Inc. and Velcera Pharmaceuticals, Inc. /Old/. He received his undergraduate degree from The Wharton School of the University of Pennsylvania.